Merck reports € 59 Million expansion in Antibody-Drug Conjugate manufacturing


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Merck reports € 59 Million expansion in Antibody-Drug Conjugate manufacturing
Merck invests in immuno oncology

Merck, a leading science and technology company, today announced the € 59 million expansion of its HPAPI and ADC manufacturing capacity at its facilities near Madison, Wisconsin , USA. The investment will allow for the large-scale manufacture of increasingly potent compounds for therapies with the potential to treat cancer. Completion is scheduled for mid-2022, and about 50 full-time jobs are expected to be created from 2021.

"ADCs have seen incredible growth in the past decade, and regulatory approval in recent years demonstrates their promise as a targeted therapy," said Andrew Bulpin , director of Process Solutions, Merck's Life Science business. "With over 35 years of experience in this area, we were pioneers in the development and manufacture of biological products, conjugation processes and small molecules. This investment reinforces our commitment to working with innovators to make new treatments available to patients more quickly and efficient".

Merck 's new 6,500 m 2 office building will be one of the largest dedicated HPAPI manufacturing facilities, specifically designed to handle single digit nanogram occupational exposure limit materials. The project is an addition to the company's Madison campus , which was the first commercial ADC facility in North America designed to handle highly active materials. The new building will join the Merck campus based in St. Louis, Missouri , USA, specializing in bioconjugation for ADC, active pharmaceutical ingredients and the manufacture of excipients and adjuvants.

ADCs are an emerging class of highly specific drugs, created with the goal of destroying cancer cells while preserving healthy ones. Today there are only nine ADCs approved globally. However, the ADC industry is experiencing solid growth and is expected to reach € 13 billion in 2030 1 .

While ADCs can provide many benefits compared to other therapeutic options, they also present a unique set of challenges. Its development is complex, requiring rigorous containment infrastructure, and its structural exceptionality requires knowledge in a series of different technologies for small and large molecules, as well as analytical resources. Due to these challenges, more than 70% of ADC projects are outsourced to organizations specialized in their development and manufacture 2 .

With more than 35 years of experience in the development and manufacture of small molecules, biological products and ADC technologies, Merck offers extensive experience in clinical and commercial manufacturing. The company's comprehensive service portfolio combines the stages of drug development and production, from pre-clinical to commercial, from a single source. This consolidation helps to reduce risks and streamlines the process of obtaining therapies for patients more quickly.

Tags : #MerckNews #LatestPharmaInventionNewsSep10 #MerckNewInvestment #AntibodyDrugConjugate #MerckImmunoOncology #HPAPI #ADCManufacturing

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026